Concepedia

Publication | Closed Access

Evaluation of Pregnancy Outcomes from the TYSABRI® (Natalizumab) Pregnancy Exposure Registry (P02.127)

DOI

26

Citations

0

References

2013

Year

Lynda M. Cristiano, Susan Friend, Carmen Bozic, Gary Bloomgren
Neurology

Abstract

OBJECTIVE: To prospectively evaluate the outcomes of pregnancy in women who are pregnant or trying to become pregnant and have been exposed to natalizumab within 90 days prior to last menstrual period (LMP).